LYKA LABS
|
The Current P/E Ratio of LYKA LABS is 107.10.
| Share Price | ₹75.5 | Jan 22,2026 |
| Market Cap | ₹269.5 Cr | |
| Earnings-TTM | ₹2.5 Cr | TTM-Consolidated Results |
| Price/Earnings | 107.10x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of LYKA LABS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹269.5 Cr] as on Jan 22,2026
(/) Earnings [ ₹2.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 107.10x ]
Thus, for LYKA LABS , the investors are currently willing to pay 107.10 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LYKA LABS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LYKA LABS over the last five years.
Historical PE (Price/Earnings) ratio chart of LYKA LABS
PE Ratio Performance Analysis for LYKA LABS
- LYKA LABS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 10.99x.
- LYKA LABS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LYKA LABS 's p/e ratio peaked in Mar2025 at 44.97x.
- LYKA LABS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does LYKA LABS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| LYKA LABS | 2.52 | 107.10 | 269.5 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 37.28 | 392,147.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 64.87 | 161,208.0 |
| CIPLA LTD | 5,453.86 | 20.31 | 110,790.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 63.64 | 136,190.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 18.44 | 101,587.0 |
| MANKIND PHARMA LTD | 1,767.06 | 50.18 | 88,662.3 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 17.90 | 89,036.6 |
| LUPIN LTD | 4,347.53 | 22.75 | 98,899.2 |
| AUROBINDO PHARMA LTD | 3,447.75 | 19.30 | 66,536.6 |
| ABBOTT INDIA LTD | 1,508.95 | 39.01 | 58,856.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LYKA LABS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.90x |
| Max industry PE | 107.10x |
| Median industry PE | 37.28x |
| Average industry PE | 41.89x |
You may also like the below Video Courses